

Vaginal irritation testing: towards regulatory acceptance of a method using reconstructed human vaginal epithelium

Jessica Perrin^{1*}, Gertrude-Emilia Costin², Seyoum Ayehunie³, Jeffrey Brown¹, and Amy J. Clippinger¹

¹PETA Science Consortium International e.V., Stuttgart, Germany

²Institute for In Vitro Sciences, Inc., Gaithersburg, USA

³MatTek Now part of Sartorius, Ashland, USA

*JPerrin@thePSCI.eu

INTRODUCTION

- Personal lubricants can be defined as substances applied to the genital area to enhance comfort during sexual activity.
- Safety testing requirements vary by region and depend on whether they are classified as medical devices.
- Biocompatibility tests supporting marketing approval for medical devices are described, among others, in standards from the International Organization for Standardization (ISO).
- In the US, personal lubricants are classified as class II medical devices, and tests required by the US Food and Drug Administration (FDA) include, among other animal tests, a rabbit vaginal irritation (RVI) test, described in ISO 10993-23:2021.
- The EpiVaginal™ (MatTek Now Part of Sartorius)¹ and the SkinEthic™ Human Vaginal Epithelium (EPISKIN) models are reconstructed human vaginal epithelium (RHVE) models that can be used as *in vitro* test systems for the safety evaluation of personal lubricants.²
- This poster proposes a qualification plan for an RHVE-based test method to support regulatory decision-making as to whether water-based personal lubricants are biocompatible with the vaginal epithelium.³

Methods

Test model: EpiVaginal™ tissue, VEC100, topical application of 100 µL of product or controls.

Exposure time: positive control 1% Triton X-100 for 0.5, 1, or 2 hours, negative controls and products for 1, 4 or 24 hours.

Readout: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

Output: percentage viability (%) and exposure time required to reduce cell viability by 50% (ET₅₀ value).




Figure 1: H&E-stained histological cross-sections of (A) EpiVaginal™, and (B) human vaginal explant

Towards Regulatory Acceptance: Qualification Plan

- There are no well-described personal lubricants known to cause vaginal irritation.
- The proposed strategy to qualify the RHVE test method involves spiking known irritants into a water-based chassis formulation.
- Interactions to promote regulatory integration in a non-product specific manner:
 - ISO Technical Committee 194
 - FDA's Medical Device Development Tool program⁴
- The qualification plan was developed with input from an industry consortium.

Table 2: Products for qualification plan step 1 and 2

Product	Label	Qualification step
Chassis formulation: 5% glycerin, 0.7% hydroxyethylcellulose, 0.19% potassium sorbate, 0.36% sodium benzoate, and 0.19% citric acid anhydrous	Acceptable	1
Chassis + 2% benzalkonium chloride (BZK)	Non-acceptable	1
Chassis + 0.1% BZK	Acceptable	1
Chassis + 2% sodium dodecyl sulfate (SDS)	Non-acceptable	1
Chassis + 8% Chlorhexidine gluconate	Non-acceptable	2
Chassis + 10% Phenoxyethanol	Non-acceptable	2
Chassis + 8% Cinnamaldehyde	Non-acceptable	2
Chassis + Glycolic acid pH = 2.5	Non-acceptable	2
Chassis + Lactic acid pH = 2.5	Non-acceptable	2
Chassis + 8% Nonoxynol-9	Non-acceptable	2
Chassis + 8% Cetrimonium chloride	Non-acceptable	2
Chassis + C31G	Non-acceptable	2
Marketed personal lubricant 4	Acceptable	2
Marketed personal lubricant 5	Acceptable	2

Results Qualification Step 1: The RHVE test method ranked spiked-in products according to their irritancy label




Figure 4: Mean tissue viability (n=3) as a function of time in the EpiVaginal™ model after exposure to chassis and spike-ins. Error bars indicate the standard deviation.

Product	Label	ET ₅₀ value
Chassis formulation	Acceptable	> 24 hours
Chassis + 2% BZK	Non-acceptable	0.02 hours
Chassis + 0.1% BZK	Acceptable	3.2 hours
Chassis + 2% SDS	Non-acceptable	1.3 hours

Table 3: ET₅₀ values and labels for products tested in qualification step 1

Results Proof-of-Concept: The RHVE test method ranked marketed products according to their irritation potential

- Three marketed water-based personal lubricants showed no reduction in tissue viability, with only a mild decrease observed for Personal lubricant 3, formulated with a sensorial ingredient.
- In contrast, vaginal contraceptives containing the known vaginal irritant nonoxynol-9 (N-9) caused decreased tissue viability.




Figure 2: Mean tissue viability (n=2) as a function of time in the EpiVaginal™ model after exposure to five different products. Error bars indicate the absolute difference between the two replicates divided by two.

Table 1: Products and controls tested in the proof-of-concept study

Product or control name	Description
Positive control	1% (w/v) Triton X-100 solution in deionized, sterile water
Negative control	Sterile deionized water or untreated tissues
Personal lubricant 1	Personal lubricant without sensorial ingredients
Personal lubricant 2	Same manufacturer and product line as personal lubricant 3, without sensorial ingredients
Personal lubricant 3	Same manufacturer and product line as personal lubricant 2, with sensorial ingredients
Vaginal contraceptive 1	Product containing 3% N-9
Vaginal contraceptive 2	Product containing 4% N-9




Figure 3: Qualification plan

Conclusions and Outlook

- The RHVE test method demonstrated the ability to rank products according to vaginal irritation potential, supporting its development as a human-relevant alternative to the rabbit vaginal irritation (RVI) test used in regulatory biocompatibility assessments.
- The data generated to date provide a scientific foundation. However, formal qualification is required to support regulatory replacement of the RVI for water-based personal lubricants.
- The ongoing qualification plan is designed to generate the data needed for regulatory confidence and integration.
- The context of use could expand to other products contacting the vaginal mucosa, such as tampons, menstrual cups⁵ or condoms.

REFERENCES

- Ayehunie, S., Cannon, C., LaRosa, K., Pudney, J., Anderson, D.J., Klausner, M., 2011. Toxicology 279, 130–138. <https://doi.org/10.1016/j.tox.2010.10.001>
- Ayehunie, S., Landry, T., Armento, A., 2024. Vitro. Cell. Dev. Biol. - Anim. 60, 569–582. <https://doi.org/10.1007/S11626-024-00907-1>
- Perrin, J., Costin, G.-E., Ayehunie, S., Kandárová, H., Landry, T., Brown, J., Clippinger, A.J., 2026. Toxicol. Vitro. 112, 106198. <https://doi.org/10.1016/j.tiv.2026.106198>
- Costin, G.E., Hill, E., Brown, J., Clippinger, A.J., 2020. Qualification of a non-animal vaginal irritation method admitted as nonclinical assessment model (NAM) in the Incubator Phase of the United States Food and Drug Administration (US FDA) Medical Devices Development Tool (MDDT). Toxicol. Vitro. 62. <https://doi.org/10.1016/j.tiv.2019.104680>
- Sica, V.P., Friberg, M.A., Teufel, A.G., Streicher-Scott, J.L., Hu, P., Sauer, U.G., Krivos, K.L., Price, J.M., Baker, T.R., Abbinante-Nissen, J.M., Woeller, K.E., 2022. eBioMedicine 86. <https://doi.org/10.1016/J.EBIOM.2022.104339>